 |
 Video: What is a Stock Split?
|
|
|
| AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. According to our AZN split history records, AstraZeneca has had 2 splits. | |
|
AstraZeneca (AZN) has 2 splits in our AZN split history database. The first split for AZN took place on April 08, 1998. This was a 3 for 1
split, meaning for each share of AZN owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 3000 share position following the split. AZN's second split took place on July 27, 2015. This was a 2 for 1 split, meaning for each share of AZN owned pre-split, the shareholder now owned 2 shares. For example, a 3000 share position pre-split, became a 6000 share position following the split.
When a company such as AstraZeneca splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the AZN split history from start to finish, an original position size of 1000 shares would have turned into 6000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AstraZeneca shares, starting with a $10,000 purchase of AZN, presented on a split-history-adjusted basis factoring in the complete AZN split history.
Growth of $10,000.00
With Dividends Reinvested
|
| Start date: |
12/11/2014 |
|
| End date: |
12/09/2024 |
|
| Start price/share: |
$36.80 |
|
| End price/share: |
$68.58 |
|
| Starting shares: |
271.74 |
|
| Ending shares: |
376.88 |
|
| Dividends reinvested/share: |
$14.18 |
|
| Total return: |
158.46% |
|
| Average Annual Total Return: |
9.96% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$25,849.98 |
|
| Years: |
10.00 |
|
| |
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/11/2014 |
|
| End date: |
12/09/2024 |
|
| Start price/share: |
$36.80 |
|
| End price/share: |
$68.58 |
|
| Dividends collected/share: |
$14.18 |
|
| Total return: |
124.90% |
|
| Average Annual Total Return: |
8.44% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$22,490.11 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 04/08/1998 | 3 for 1
| | 07/27/2015 | 2 for 1 |
|
|
Free AZN Email Alerts:
